177 related articles for article (PubMed ID: 32145440)
1. Rationale and design of the granulocyte-macrophage colony stimulating factor in peripheral arterial disease (GPAD-3) study.
Mehta A; Mavromatis K; Ko YA; Rogers SC; Dhindsa DS; Goodwin C; Patel R; Martini MA; Prasad M; Mokhtari A; Hesaroieh IG; Frohwein SC; Kutner MH; Harzand A; Wells BJ; Duwayri Y; Alabi O; Rajani RR; Brewster LP; Waller EK; Quyyumi AA
Contemp Clin Trials; 2020 Apr; 91():105975. PubMed ID: 32145440
[TBL] [Abstract][Full Text] [Related]
2. Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial.
Poole J; Mavromatis K; Binongo JN; Khan A; Li Q; Khayata M; Rocco E; Topel M; Zhang X; Brown C; Corriere MA; Murrow J; Sher S; Clement S; Ashraf K; Rashed A; Kabbany T; Neuman R; Morris A; Ali A; Hayek S; Oshinski J; Yoon YS; Waller EK; Quyyumi AA
JAMA; 2013 Dec; 310(24):2631-9. PubMed ID: 24247554
[TBL] [Abstract][Full Text] [Related]
3. Effect of Granulocyte-Macrophage Colony-Stimulating Factor With or Without Supervised Exercise on Walking Performance in Patients With Peripheral Artery Disease: The PROPEL Randomized Clinical Trial.
McDermott MM; Ferrucci L; Tian L; Guralnik JM; Lloyd-Jones D; Kibbe MR; Polonsky TS; Domanchuk K; Stein JH; Zhao L; Taylor D; Skelly C; Pearce W; Perlman H; McCarthy W; Li L; Gao Y; Sufit R; Bloomfield CL; Criqui MH
JAMA; 2017 Dec; 318(21):2089-2098. PubMed ID: 29141087
[TBL] [Abstract][Full Text] [Related]
4. Racial Differences in the Effect of Granulocyte Macrophage Colony-Stimulating Factor on Improved Walking Distance in Peripheral Artery Disease: The PROPEL Randomized Clinical Trial.
McDermott MM; Polonsky TS; Guralnik JM; Ferrucci L; Tian L; Zhao L; Stein J; Domanchuk K; Criqui MH; Taylor DA; Li L; Kibbe MR
J Am Heart Assoc; 2019 Jan; 8(2):e011001. PubMed ID: 30661439
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial disease.
Subramaniyam V; Waller EK; Murrow JR; Manatunga A; Lonial S; Kasirajan K; Sutcliffe D; Harris W; Taylor WR; Alexander RW; Quyyumi AA
Am Heart J; 2009 Jul; 158(1):53-60.e1. PubMed ID: 19540392
[TBL] [Abstract][Full Text] [Related]
6. Progenitor cell release plus exercise to improve functional performance in peripheral artery disease: the PROPEL Study.
Domanchuk K; Ferrucci L; Guralnik JM; Criqui MH; Tian L; Liu K; Losordo D; Stein J; Green D; Kibbe M; Zhao L; Annex B; Perlman H; Lloyd-Jones D; Pearce W; Taylor D; McDermott MM
Contemp Clin Trials; 2013 Nov; 36(2):502-9. PubMed ID: 24080099
[TBL] [Abstract][Full Text] [Related]
7. START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease.
van Royen N; Schirmer SH; Atasever B; Behrens CY; Ubbink D; Buschmann EE; Voskuil M; Bot P; Hoefer I; Schlingemann RO; Biemond BJ; Tijssen JG; Bode C; Schaper W; Oskam J; Legemate DA; Piek JJ; Buschmann I
Circulation; 2005 Aug; 112(7):1040-6. PubMed ID: 16087795
[TBL] [Abstract][Full Text] [Related]
8. Design of the START-trial: STimulation of ARTeriogenesis using subcutaneous application of GM-CSF as a new treatment for peripheral vascular disease. A randomized, double-blind, placebo-controlled trial.
van Royen N; Piek JJ; Legemate DA; Schaper W; Oskam J; Atasever B; Voskuil M; Ubbink D; Schirmer SH; Buschmann I; Bode C; Buschmann EE
Vasc Med; 2003; 8(3):191-6. PubMed ID: 14989560
[TBL] [Abstract][Full Text] [Related]
9. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group.
Angel JB; High K; Rhame F; Brand D; Whitmore JB; Agosti JM; Gilbert MJ; Deresinski S
AIDS; 2000 Mar; 14(4):387-95. PubMed ID: 10770541
[TBL] [Abstract][Full Text] [Related]
10. Protocol for the Stimulating β
Bubb KJ; Harmer JA; Finemore M; Aitken SJ; Ali ZS; Billot L; Chow C; Golledge J; Mister R; Gray MP; Grieve SM; Hamburg N; Keech AC; Patel S; Puttaswamy V; Figtree GA
BMJ Open; 2021 Sep; 11(9):e049858. PubMed ID: 34588252
[TBL] [Abstract][Full Text] [Related]
11. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis.
Tazawa R; Ueda T; Abe M; Tatsumi K; Eda R; Kondoh S; Morimoto K; Tanaka T; Yamaguchi E; Takahashi A; Oda M; Ishii H; Izumi S; Sugiyama H; Nakagawa A; Tomii K; Suzuki M; Konno S; Ohkouchi S; Tode N; Handa T; Hirai T; Inoue Y; Arai T; Asakawa K; Sakagami T; Hashimoto A; Tanaka T; Takada T; Mikami A; Kitamura N; Nakata K
N Engl J Med; 2019 Sep; 381(10):923-932. PubMed ID: 31483963
[TBL] [Abstract][Full Text] [Related]
12. Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease: The TELEX Randomized Clinical Trial.
McDermott MM; Bazzano L; Peterson CA; Sufit R; Ferrucci L; Domanchuk K; Zhao L; Polonsky TS; Zhang D; Lloyd-Jones D; Leeuwenburgh C; Guralnik JM; Kibbe MR; Kosmac K; Criqui MH; Tian L
JAMA; 2022 Oct; 328(13):1315-1325. PubMed ID: 36194220
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study.
Seiler C; Pohl T; Wustmann K; Hutter D; Nicolet PA; Windecker S; Eberli FR; Meier B
Circulation; 2001 Oct; 104(17):2012-7. PubMed ID: 11673338
[TBL] [Abstract][Full Text] [Related]
15. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
Ryu JK; Swann S; LeVeque F; Scarantino CW; Johnson D; Chen A; Fortin A; Pollock J; Kim H; Ang KK
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):643-50. PubMed ID: 17293228
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma.
Advani R; Chao NJ; Horning SJ; Blume KG; Ahn DK; Lamborn KR; Fleming NC; Bonnem EM; Greenberg PL
Ann Intern Med; 1992 Feb; 116(3):183-9. PubMed ID: 1345803
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of subcutaneous-only granulocyte-macrophage colony-stimulating factor for collateral growth promotion in patients with coronary artery disease.
Zbinden S; Zbinden R; Meier P; Windecker S; Seiler C
J Am Coll Cardiol; 2005 Nov; 46(9):1636-42. PubMed ID: 16256861
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells.
Winter JN; Lazarus HM; Rademaker A; Villa M; Mangan C; Tallman M; Jahnke L; Gordon L; Newman S; Byrd K; Cooper BW; Horvath N; Crum E; Stadtmauer EA; Conklin E; Bauman A; Martin J; Goolsby C; Gerson SL; Bender J; O'Gorman M
J Clin Oncol; 1996 Jan; 14(1):277-86. PubMed ID: 8558209
[TBL] [Abstract][Full Text] [Related]
19. Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease.
Aglietta M; Montemurro F; Fagioli F; Volta C; Botto B; Cantonetti M; Racanelli V; Teofili L; Ferrara R; Amadori S; Castoldi GL; Dammacco F; Levis A
Cancer; 2000 Jan; 88(2):454-60. PubMed ID: 10640980
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
